RBC Capital Increases Auxilium Pharmaceuticals Price Target to $33.00 (AUXL)
Analysts at RBC Capital hoisted their price target on shares of Auxilium Pharmaceuticals (NASDAQ:AUXL) from $28.00 to $33.00 in a research report issued to clients and investors on Wednesday, American Banking News.com reports. The firm currently has an “outperform” rating on the stock. RBC Capital’s target price would suggest a potential upside of 10.00% from the stock’s previous close.
AUXL has been the subject of a number of other recent research reports. Analysts at Mizuho raised their price target on shares of Auxilium Pharmaceuticals from $30.00 to $36.00 in a research note on Monday. They now have a “buy” rating on the stock. Separately, analysts at MKM Partners downgraded shares of Auxilium Pharmaceuticals from a “buy” rating to a “neutral” rating in a research note on Thursday, January 23rd. They now have a $23.00 price target on the stock. They noted that the move was a valuation call. Finally, analysts at UBS AG raised their price target on shares of Auxilium Pharmaceuticals from $23.00 to $30.00 in a research note on Friday, January 17th. They now have a “buy” rating on the stock. Five analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company’s stock. Auxilium Pharmaceuticals currently has an average rating of “Buy” and a consensus target price of $24.86.
Auxilium Pharmaceuticals (NASDAQ:AUXL) opened at 30.00 on Wednesday. Auxilium Pharmaceuticals has a 1-year low of $13.87 and a 1-year high of $30.05. The stock’s 50-day moving average is $24.94 and its 200-day moving average is $20.22. The company has a market cap of $1.482 billion and a price-to-earnings ratio of 13.23.
Auxilium Pharmaceuticals, Inc is a specialty biopharmaceutical company focuses on developing and marketing products to predominantly specialist audiences.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.